Currency In USD
| Previous Close | 3.22 |
| Open | 3.2 |
| Day High | 3.27 |
| Day Low | 3.18 |
| 52-Week High | 4.23 |
| 52-Week Low | 1.4 |
| Volume | 2.48M |
| Average Volume | 4.67M |
| Market Cap | 529.93M |
| PE | -2.07 |
| EPS | -1.57 |
| Moving Average 50 Days | 2.89 |
| Moving Average 200 Days | 2.87 |
| Change | 0.03 |
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio Announces 2026 Strategic Priorities
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automate